Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

BIOCYTOGEN PHARMACEUTICALS (BEIJING) CO., LTD.

百奧賽圖(北京)醫藥科技股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2315)

ANNOUNCEMENT ON PRELIMINARY FINANCIAL DATA FOR THE SIX MONTHS ENDED JUNE 30, 2025

This announcement is made by Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (the "**Company**") pursuant to the Inside Information Provisions (as defined under the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**")) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) and Rule 13.09 of the Listing Rules.

The major financial data of the Company and its subsidiaries (together, the "**Group**") for the six months ended June 30, 2025 as set out in this announcement are preliminary financial data prepared in accordance with the International Financial Reporting Standards, and have not been audited by the auditor of the Company. As a result, there may be differences between the financial data mentioned in this announcement and those to be disclosed in the interim results announcement of the Group for the six months ended June 30, 2025. The final interim data should be those to be disclosed in the latter. Investors are hereby reminded of the investment risks.

I. ESTIMATED RESULTS FOR THE PERIOD

(I) Period of estimated results

From January 1, 2025 to June 30, 2025

(II) Estimated results

1. It is expected that the revenue of the Group in the first half of 2025 will be ranging from approximately RMB616.0 million to RMB626.0 million and will increase by approximately RMB205.5 million to RMB215.5 million as compared with the data in the financial statements for the corresponding period of last year, representing a period-on-period increase of approximately 50.1% to 52.5%.

2. It is expected that the net profit of the Group for the six months ended June 30, 2025 will be ranging from approximately RMB42.7 million to RMB52.7 million, representing a turnaround from loss to profit on a period-to-period basis.

3. It is expected that the research and development expenses of the Group in the first half of 2025 will be ranging from approximately RMB206.1 million to RMB216.1 million and will increase by approximately RMB44.4 million to RMB54.4 million as compared with the data in the financial statements for the corresponding period of last year, representing a period-on-period increase of approximately 27.5% to 33.6%.

II. INTERIM RESULTS FOR THE CORRESPONDING PERIOD OF LAST YEAR

(I) The revenue of the Group for the six months ended June 30, 2024: approximately RMB410.5 million

(II) The loss for the year of the Group for the six months ended June 30, 2024: approximately RMB50.7 million

(III) The research and development expenses of the Group for the six months ended June 30, 2024: approximately RMB161.7 million

III. MAIN REASONS FOR THE ESTIMATED GROWTH IN RESULTS DURING THE PERIOD

The board (the "**Board**") of directors (the "**Director(s)**") of the Company considers that the results of the Company have maintained good growth, mainly attributable to the following factors:

(I) The Company remains firmly committed to its strategic objective of "driving new drug development through innovative technologies". Rooted in China and serving the global market, the Company is dedicated to becoming a global headstream of new drugs. The Company continues to maintain a high level of R&D investment and continuously adjusts its total R&D expenditure and key R&D focuses in line with its development pace and strategy. By doing so, it consistently provides globally competitive, high-quality R&D products and services for both domestic and international biopharmaceutical enterprises, sustaining its business competitiveness while driving continuous and rapid business growth;

(II) In the first half of 2025, the Company further expanded its presence in overseas markets. The ongoing expansion of the sales team and the improvement of the sales system supported sustained and rapid growth in overseas business. Meanwhile, domestic biopharmaceutical enterprises released greater R&D demand in the first half of 2025, and the Company was able to provide innovative R&D products and services to better meet customer needs, maintaining rapid growth in its domestic business. Revenue from the preclinical products and services business segment, which focuses on innovative animal models, as well as from the antibody molecule transfer and development business segment, recorded rapid growth in both domestic and international markets in the first half of 2025, while maintaining a high gross profit margin;

(III) The Company continues to implement lean management. On one hand, it adjusted and optimized its management team along with the changes in its business operations to enhance operational efficiency, resulting in a continued decline in the administrative expense ratio. On the other hand, by organizing its R&D and production activities more rationally, the Company improved the efficiency of human resource utilization across its R&D and production lines, thereby more efficiently realizing the transformation from innovative R&D to commercial production. The continued implementation of these measures has significantly enhanced the Company's profitability.

IV. RISK WARNING

The above preliminary financial data are only preliminary accounting data, which has not been audited or reviewed by the auditor of the Company. The final interim financial data will be disclosed in the interim results announcement of the Group for the six months ended June 30, 2025 and the 2025 interim report. Investors are advised to pay attention to such investment risks.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
Shen Yuelei
Chairman of the Board, Chief Executive Officer and Executive Director

Hong Kong, August 4, 2025

As at the date of this announcement, the board of the Company comprises Dr. Shen Yuelei as chairman, chief executive officer and executive Director, Dr. Ni Jian and Dr. Zhang Haichao as executive Directors; Mr. Wei Yiliang, Dr. Zhou Kexiang and Ms. Zhang Leidi as non-executive Directors; Mr. Hua Fengmao, Dr. Yu Changyuan and Ms. Liang Xiaoyan as independent non-executive Directors.